Drug Type Small molecule drug |
Synonyms Malol, Prunol, Urson + [2] |
Target |
Action inhibitors |
Mechanism FADS2 inhibitors(fatty acid desaturase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC30H48O3 |
InChIKeyWCGUUGGRBIKTOS-GPOJBZKASA-N |
CAS Registry77-52-1 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Ursolic Acid | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metabolic Syndrome | Phase 2 | Mexico | 01 Sep 2014 | |
| Stomach Cancer | Preclinical | China | 01 Jul 2025 | |
| Parkinson Disease | Preclinical | India | 24 Jun 2025 | |
| Parkinson Disease | Preclinical | India | 24 Jun 2025 | |
| Non-Small Cell Lung Cancer | Preclinical | China | 27 May 2025 | |
| Castration-Resistant Prostatic Cancer | Preclinical | United States | 28 Apr 2025 |
Phase 2 | 10 | Strength Training+Ursolic Acid (UA and Exercise in Paraplegia Group) | ijerszzqqd(wilufhinfa) = mippmttkas zniehuxnwp (hnojemkkin, 2642.65) View more | - | 21 May 2025 | ||
(UA in Tetraplegia Group) | ijerszzqqd(wilufhinfa) = pznaoqzyjo zniehuxnwp (hnojemkkin, 1885.21) View more | ||||||
Phase 2/3 | - | (UA supplementation) | yukhhgqzwp(ewomjrphrj) = wmocmjflov hsrukajhfy (mlwmsacmdq ) | Negative | 01 Aug 2021 | ||
(Placebo supplementation) | - | ||||||
Phase 2 | 24 | (Ursolic Acid) | cwnakmeuwe(xuhkogybwn) = yrkntvrrwj gkbhaagmxp (mlovgbcedt, 1.2) View more | - | 08 Oct 2020 | ||
Placebo (Placebo) | cwnakmeuwe(xuhkogybwn) = ocmhixpxgu gkbhaagmxp (mlovgbcedt, 1.4) View more |





